SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence
- PMID: 8441409
- PMCID: PMC359485
- DOI: 10.1128/mcb.13.3.1728-1736.1993
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence
Abstract
P210 BCR/ABL is a chimeric oncogene implicated in the pathogenesis of chronic myelogenous leukemia. BCR sequences have been shown to be required for activation of the tyrosine kinase and transforming functions of BCR/ABL. In this work, we show that two other structural requirements for full transforming activity of P210 BCR/ABL include a functional tyrosine kinase and the presence of tyrosine 1294, a site of autophosphorylation within the tyrosine kinase domain. Replacement of tyrosine 1294 with phenylalanine (1294F) greatly diminishes the transforming activity of BCR/ABL without affecting the specific activity of the protein tyrosine kinase. Expression of an exogenous myc gene in fibroblasts partially complements the transforming capacity of mutant P210 BCR/ABL (1294F). Surprisingly, tyrosine 1294 is not required for efficient induction of growth factor-independence in hematopoietic cell lines by P210 BCR/ABL. These results suggest that autophosphorylation at tyrosine 1294 may be important for recognition and phosphorylation of cellular substrates in the pathway of transformation, but it is not critical for mediating the events which lead to growth factor independence.
Similar articles
-
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.Blood. 1993 Sep 15;82(6):1838-47. Blood. 1993. PMID: 7691239
-
Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.Mol Cell Biol. 1998 May;18(5):2965-75. doi: 10.1128/MCB.18.5.2965. Mol Cell Biol. 1998. PMID: 9566916 Free PMC article.
-
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.Exp Hematol. 1993 Oct;21(11):1460-6. Exp Hematol. 1993. PMID: 8405226
-
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Adv Exp Med Biol. 2003;532:121-40. doi: 10.1007/978-1-4615-0081-0_11. Adv Exp Med Biol. 2003. PMID: 12908554 Review.
-
A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.Hum Cell. 1996 Dec;9(4):333-6. Hum Cell. 1996. PMID: 9183666 Review.
Cited by
-
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Biochim Biophys Acta. 2008 Jan;1785(1):63-84. doi: 10.1016/j.bbcan.2007.10.003. Epub 2007 Oct 16. Biochim Biophys Acta. 2008. PMID: 17980712 Free PMC article. Review.
-
IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11630-5. doi: 10.1073/pnas.2035020100. Epub 2003 Sep 19. Proc Natl Acad Sci U S A. 2003. PMID: 14500898 Free PMC article.
-
DNA sequence and analysis of human chromosome 9.Nature. 2004 May 27;429(6990):369-74. doi: 10.1038/nature02465. Nature. 2004. PMID: 15164053 Free PMC article.
-
Oncogenic activation of c-ABL by mutation within its last exon.Mol Cell Biol. 1993 Aug;13(8):4967-75. doi: 10.1128/mcb.13.8.4967-4975.1993. Mol Cell Biol. 1993. PMID: 8336729 Free PMC article.
-
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.Genes Dev. 1998 Apr 1;12(7):968-81. doi: 10.1101/gad.12.7.968. Genes Dev. 1998. PMID: 9531535 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous